SCHEMBL16243753

SCHEMBL16243753

COC1CCN(c2ccc3ncc(C(=O)O)n3n2)C1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 4/20 0.44
▸ ADRA1A P35348 3/20 0.43
▸ IRAK4 Q9NWZ3 3/20 0.42
▸ PRKAB2 O43741 2/20 0.40
▸ PRKAG1 P54619 2/20 0.40
▸ PRKAA2 P54646 2/20 0.40
▸ PRKAA1 Q13131 2/20 0.40
▸ PRKAG3 Q9UGI9 2/20 0.40
▸ PRKAG2 Q9UGJ0 2/20 0.40
▸ PRKAB1 Q9Y478 2/20 0.40
▸ NTRK1 P04629 3/20 0.39
▸ PIK3CA P42336 1/20 0.37
▸ PTGER4 P35408 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ PIM1 P11309 1/20 0.37
▸ NTRK3 Q16288 1/20 0.37
▸ NTRK2 Q16620 1/20 0.37
▸ ACACB O00763 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14896984 1.00 AAK1 (0.44) AAK1ADRA1AIRAK4PRKAB2PRKAG1
SCHEMBL14881458 0.83 IRAK4 (0.47) AAK1IRAK4NTRK1PIM1NTRK3
SCHEMBL14881490 0.83 IRAK4 (0.47) AAK1IRAK4NTRK1PIM1NTRK3
SCHEMBL26129364 0.82 AAK1 (0.41) AAK1ADRA1ANTRK1PIM1
SCHEMBL14897314 0.81 IRAK4 (0.46) AAK1IRAK4NTRK1NTRK3NTRK2
SCHEMBL16180116 0.81 IRAK4 (0.45) AAK1ADRA1AIRAK4NTRK1NTRK3
SCHEMBL16180114 0.81 IRAK4 (0.45) AAK1ADRA1AIRAK4NTRK1NTRK3
SCHEMBL14897317 0.81 IRAK4 (0.45) AAK1IRAK4NTRK1NTRK3NTRK2
SCHEMBL14897275 0.81 IRAK4 (0.47) AAK1ADRA1AIRAK4NTRK1HRH3
SCHEMBL14897203 0.80 IRAK4 (0.44) AAK1IRAK4NTRK1NTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 AAK1 2011/4885ADRA1A 3762/4885IRAK4 3168/4885
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 AAK1 2011/4885ADRA1A 3762/4885IRAK4 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback